Y Mabs Therapeutics Stock Investor Sentiment

YMAB Stock  USD 10.01  0.27  2.63%   
About 75% of Y MAbs' investor base is looking to short. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Y MAbs Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Y MAbs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at finance.yahoo.com         
Why Y-mAbs Therapeutics Stock Got Mashed on Monday
Yahoo News
over three months ago at news.google.com         
YMAB LAWSUIT ALERT Levi Korsinsky Notifies Y-mAbs Therapeutics, Inc. Investors of a Class Action Law...
Google News at Macroaxis
over three months ago at finance.yahoo.com         
Y-mAbs Therapeutics, Inc. One of Caligan Partners Top Holdings Now?
Yahoo News
over three months ago at zacks.com         
Celldex Therapeutics Reports Q2 Loss, Tops Revenue Estimates
zacks News
over three months ago at globenewswire.com         
Y-mAbs to Participate in Upcoming Investor Conferences in August
Macroaxis News: globenewswire.com
over three months ago at simplywall.st         
Y-mAbs Therapeutics pulls back 11 percent this week, but still delivers shareholders decent 90 perce...
Simply Wall St News at Macroaxis
over three months ago at benzinga.com         
Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast
benzinga news
over three months ago at news.google.com         
Short Interest in Y-mAbs Therapeutics, Inc. Rises By 18.1 percent - MarketBeat
Google News at Macroaxis
over three months ago at news.google.com         
Ameritas Investment Partners Inc. Has 60,000 Position in Y-mAbs Therapeutics, Inc. - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
SG Americas Securities LLC Trims Position in Y-mAbs Therapeutics, Inc. - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Y-mAbs Therapeutics Finalizes CFO Transition and Advisory Deal - TipRanks
Google News at Macroaxis
over three months ago at benzinga.com         
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs ...
benzinga news
over three months ago at benzinga.com         
Acquisition by Bo Kruse of 108900 shares of Y MAbs at 9.83 subject to Rule 16b-3
benzinga news
over three months ago at www.macroaxis.com         
Acquisition by Rajah Vignesh of 17800 shares of Y MAbs subject to Rule 16b-3
Macroaxis News
over three months ago at simplywall.st         
Were Not Worried About Y-mAbs Therapeutics Cash Burn
Simply Wall St News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Y MAbs that are available to investors today. That information is available publicly through YMAB media outlets and privately through word of mouth or via YMAB internal channels. However, regardless of the origin, that massive amount of YMAB data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Y MAbs news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Y MAbs relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Y MAbs' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Y MAbs alpha.

Y MAbs Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Insider Selling Y-mAbs Therapeutics, Inc. Insider Sells 65,000 Shares of Stock
09/18/2024
2
Disposition of 22831 shares by Thomas Gad of Y MAbs at 4.38 subject to Rule 16b-3
09/19/2024
3
Insider Trading
09/27/2024
4
Disposition of 722 shares by Ber Gerard of Y MAbs at 12.0 subject to Rule 16b-3
10/04/2024
5
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA in Japan
11/04/2024
6
What To Expect From Y-mAbs Therapeutics Inc Q3 2024 Earnings
11/07/2024
7
Paradigm Biocapital Advisors LP Bolsters Position in Y-mAbs Therapeutics Inc
11/15/2024
8
The Market Doesnt Like What It Sees From Y-mAbs Therapeutics, Inc.s Revenues Yet As Shares Tumble 26
11/19/2024
9
Y-mAbs Omburtamab Failure The Critical Turning Point And 19.65M Shareholder Settlement
11/22/2024
10
Y-mAbs to Participate at Citis 2024 Global Healthcare Conference
11/27/2024
11
Acquisition by Wg Biotech Aps of 30671 shares of Y MAbs at 5.8125 subject to Rule 16b-3
12/06/2024
12
We Think Y-mAbs Therapeutics Can Afford To Drive Business Growth
12/10/2024

Complementary Tools for YMAB Stock analysis

When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Global Correlations
Find global opportunities by holding instruments from different markets